Antiphospholipid syndrome in people 65 and older who had an ischemic stroke
Official title: A Prospective, Single-center Cohort Study to Determine the Prevalence and Consequences of Antiphospholipid Syndrome in Patients Aged 65 and Over With Ischemic Strokes (IS)
Run by CHU de Reims · NCT07163338 · Data updated 2026-11-12
This study will test whether routine blood testing for antiphospholipid antibodies in people aged 65 and over hospitalized with ischemic stroke or TIA can identify previously unrecognized antiphospholipid syndrome.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 65 Years and up |
| Sex | All |
| Enrollment | 400 (estimated) |
| Sponsor | CHU de Reims Academic / other |
| Locations | 1 site (Reims) |
| Status | Recruiting |
| Started | September 16, 2025 |
| Main results expected | December 16, 2027 |
| Study ends | March 16, 2028 |
| Registry record updated | November 25, 2025 |
| Trial ID | NCT07163338 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Ideal candidates are people aged 65 or older who are hospitalized for ischemic stroke or TIA, able to provide consent, and registered with the social security system.
✕Probably not a fit
Patients whose stroke cause is clearly explained by other factors (for example atrial fibrillation or advanced atherosclerosis) or who cannot undergo testing or long-term anticoagulation are less likely to gain direct benefit from this screening.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
The study will enroll patients aged 65 and older who are hospitalized for ischemic stroke or transient ischemic attack and collect blood samples for antiphospholipid antibody testing (anti-cardiolipin, anti-β2-glycoprotein I, and lupus anticoagulant). Researchers will determine the prevalence of positive antibody results in this older population and relate antibody presence to clinical features, stroke etiology, and short-term outcomes. Collected biological data will be compared with patients' clinical records to explore associations with arterial thrombosis and risk factors. Findings aim to inform whether routine screening in this age group uncovers treatable causes that change secondary prevention.
Why it matters
Potential benefit: If successful, the study could uncover previously unrecognized antiphospholipid syndrome in older stroke patients, which may lead to changes in long-term anticoagulation and potentially reduce recurrent thrombosis risk.
How similar studies have gone: Prior work shows antiphospholipid syndrome explains a notable share of ischemic strokes in younger patients, but systematic data and outcomes for routine screening in people aged 65 and over are limited.
Who can join: the full rules
Show full inclusion / exclusion criteria
inclusion criteria : * patients aged 65 and over during the inclusion phase * hospitalized for a TIA/ischemic stroke in neurology or internal medicine department during the inclusion phase * affiliated with social security system exclusion criteria : * patients under 65 years old * under legal guardianship, curatorship, or tutorship * incarcerated * under psychiatric care * admitted to a healthcare or social institution
Where it's running
-
Damien JOLLY
Reims, France Recruiting
Study contacts
- Study coordinator: Kévin DIDIER
- Email: kdidier@chu-reims.fr
- Phone: 03 26 83 24 44
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Thrombocytopenia Trajectories in antiphospholipid syndrome
This study tests whether patterns in platelet counts over time can predict outcomes for adults with antiphospholipid syndrome.
-
BCT301 CAR-iT cell therapy for hard-to-treat autoimmune diseases
This early‑phase study tests whether off-the-shelf BCT301 CAR-iT cells can be given safely to adults with refractory autoimmune diseases to see if they can be tolerated and what dose works best.
-
Characterization of Autoreactive B Cells in Autoimmune Diseases and Immune Deficiencies
Researchers are testing to see how autoreactive B cells behave in people with autoimmune diseases or immune deficiencies to better understand how these cells may contribute to disease.
-
YTS109 cell therapy for relapsed or treatment‑resistant autoimmune diseases
This will try a single infusion of YTS109 immune cells in adults 18–65 with relapsed or treatment‑resistant autoimmune diseases such as lupus, Sjogren’s, systemic sclerosis, inflammatory myopathies, or ANCA‑associated vasculitis.
-
YTS109 cell therapy for relapsed or refractory autoimmune diseases
This will try a single infusion of YTS109 immune cells to see if they are safe and help adults 18–65 with relapsed or refractory lupus (including lupus nephritis), Sjogren's syndrome, inflammatory myopathy, or ANCA‑associated vasculitis.
-
Hematological Markers MPV, PLR, and NLR in Primary Versus Secondary APS
This study tests whether blood markers MPV, PLR, and NLR differ between people with primary antiphospholipid syndrome and those with APS secondary to another autoimmune disease.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.